Itamar Medical, Inc.

Itamar Medical, Inc., a foreign-owned, for-profit medical technology manufacturer headquartered in Atlanta, Georgia, supplies home sleep apnea testing devices and diagnostic equipment to the federal government as a prime contractor across medical equipment and supplies GSA Schedules and regional VA indefinite delivery vehicles, with no set-aside designations and minimal subcontractor engagement.

Itamar Medical is a subsidiary of the Israeli parent Itamar Medical LTD and operates as a manufacturer of medical diagnostic devices under primary NAICS categories 334517 (Surgical and Medical Instrument Manufacturing) and 334512 (Electromedical and Electrotherapeutic Apparatus Manufacturing). The company competes full-and-open on federal opportunities; 100 percent of recent awards are prime contracts. Itamar Medical's core federal offering centers on the WatchPAT series of portable, at-home sleep apnea testing devices, the EndoPAT cardiovascular diagnostic platform, and associated consumable supplies and interpretation services. Representative prime contracts include a $998.6 million delivery order from Veterans Integrated Service Network 1 for Connecticut WatchPAT ONE devices (awarded September 2025, completion September 2030), a $957.6 thousand purchase order from VISN 20 for at-home sleep testing services at Puget Sound VAMC (awarded September 2024), and a $549.6 thousand delivery order from VISN 8 for sleep study monitors (awarded May 2026). The company also holds a $24.25 million multiple-award Federal Supply Schedule contract (FSS-65-II-A, Medical Equipment and Supplies) running through April 2028 and a $1.971 million single-award BPA with VISN 20 for WatchPAT ONE devices through September 2027.

Customer concentration is acute and regionally fragmented within the VA system. The top five VA regional networks account for 46 percent of all awards but diverge sharply in dollar concentration: VISN 12 anchors 89 percent of combined potential value at $51.4 million across only eight awards, while VISN 20 places 20 awards worth $9.1 million and VISN 10 places 37 awards worth $6.4 million. This concentration pattern reflects VISN 12's role as a high-dollar procurement hub. Itamar Medical serves 38 distinct customer agencies across federal sources, but the Department of Veterans Affairs dominates the footprint; 232 total awards span VA VISNs, the Defense Health Agency, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institutes of Health. Non-VA federal presence is minimal and episodic—a $27.8 thousand NIDDK purchase order for EndoPAT devices (June 2024) and a $17.1 thousand Defense Health Agency delivery order for portable polysomnography (June 2024) represent the full non-VA prime footprint in recent records.

Vehicle positioning is dominated by GSA Schedule FSS-65-II-A (Medical Equipment and Supplies), which carries 123 task orders worth $18.7 million in combined potential value. Single-award IDCs with regional VA networks provide a secondary ordering vehicle; four named IDCs ranging from $210 thousand to $1.1 million in combined potential value across multiple delivery orders support recurring supply streams. The FSS-65-II-A and supporting VA BPA vehicles enable direct ordering by regional networks without formal competition, positioning Itamar Medical as an incumbent supplier across the VA's distributed procurement model.

Activity has remained volatile over the past five fiscal years—17 awards in 2022 declined to nine in 2024 but rebounded to 16 in 2025 and 12 in 2026 through mid-September. Ten awards with combined potential value of $2.8 million face ultimate completion inside the next twenty-four months and therefore represent near-term recompete exposure. SCI-reportable invoiced revenue on service contracts above the $150,000 threshold totaled $1.4 million across FY2023–FY2024, with federal services workforce at 0.4 FTEs in FY2024. On federal services contracts captured in SCI, government-paid hourly rates ran median around $1,290.56/hr, with senior labor reaching $18,331.68/hr at the 90th percentile. SCI data represents only service contracts above the reporting threshold; the bulk of Itamar Medical's federal revenue derives from goods procurement—devices, supplies, and disposable equipment—which falls outside SCI scope. Across SCI-reportable prime contracts, the vendor performed 100 percent of contractor hours in-house with zero named subcontractor engagement.

Itamar Medical has no federal grant prime footprint but holds one sub-award recipient role: a January 2026 sub-grant from Research Triangle Institute (prime grantee) identified as PO RTI1004296. The company's federal posture is product-centric and supply-chain dependent; capability is anchored to WatchPAT and EndoPAT hardware, firmware, and ancillary services rather than staffing-intensive professional services. Growth trajectory and recompete risk track with VA budget allocations for sleep disorder diagnostics and home-based testing expansion initiatives.